Tadalafil Tablet
Product Images NDC 50090-7152

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-7152). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil, showing its molecular framework including fused rings and functional groups characteristic of the active ingredient in the drug TADALAFIL 20 mg tablets by A-S Medication Solutions.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs showing the difference in blood pressure measurements (systolic and diastolic) between tadalafil and placebo over time in hours. The graphs compare standing and supine positions, plotting the difference in mmHg from 0 to 96 hours.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs depicting changes in systolic blood pressure (BP) over time post-dose (in hours) for standing (top graph) and supine (bottom graph) positions. Each graph compares the effects of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg, showing BP changes from 0 to 24 hours after dosing.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

Line graph depicting changes in systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo, each combined with 8 mg doxazosin. The x-axis shows time after administration, and the y-axis measures systolic blood pressure, with four lines representing different treatment-time combinations.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The graph includes error bars indicating variability at each time point.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph displaying change from baseline in IPSS Total Score over 12 weeks. The graph compares Tadalafil tablets 5 mg to placebo, with the vertical axis showing score change and the horizontal axis showing treatment duration in weeks. The Tadalafil group shows a greater decrease in score compared to placebo, with statistical significance indicated near week 12 (p<0.01).*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph showing change from baseline in IPSS total score over treatment duration in weeks, comparing tadalafil tablets 5 mg to placebo. The graph indicates a greater reduction in score for tadalafil, with data points at 0, 1, 4, 8, and 12 weeks. A significance marker (p<0.01) is noted at week 4.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line chart comparing least squares mean change from baseline over weeks of therapy (0 to 26 weeks) between two groups: Tadalafil/Finasteride and Placebo/Finasteride. The chart shows data points at weeks 4, 12, and 26, indicating greater reductions for the Tadalafil/Finasteride group compared to Placebo/Finasteride, with statistical significance annotations (p<0.001 and p<0.05) at some points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment with tadalafil tablets 5 mg versus placebo. The x-axis shows duration of treatment in weeks, and the y-axis shows change from baseline in IPSS total score. The graph indicates greater reduction in score with tadalafil compared to placebo, with a statistically significant difference at 12 weeks (p < 0.01).*

FDA Label Image

Label Image (Lbl500907152)

Label for TADALAFIL 20 mg oral tablets by A-S Medication Solutions. The label indicates each tablet contains 20 mg of tadalafil. Storage instructions specify to keep the product between 68 to 77 degrees Fahrenheit. The package contains 30 tablets. The label also includes a QR code and product lot and identification numbers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.